First Light Asset Management LLC trimmed its holdings in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 7.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 452,324 shares of the company’s stock after selling 37,522 shares during the period. Omnicell comprises approximately 1.1% of First Light Asset Management LLC’s holdings, making the stock its 27th largest holding. First Light Asset Management LLC’s holdings in Omnicell were worth $18,780,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Nykredit A S acquired a new stake in shares of Omnicell during the second quarter worth approximately $26,000. Raymond James Financial Inc. bought a new stake in shares of Omnicell in the second quarter worth $26,000. Versant Capital Management Inc raised its holdings in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after acquiring an additional 294 shares in the last quarter. Clearstead Advisors LLC raised its holdings in Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in Omnicell during the 4th quarter valued at $58,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several brokerages have weighed in on OMCL. Piper Sandler reissued an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research note on Monday. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Finally, Wells Fargo & Company lowered their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.86.
Omnicell Stock Down 0.7%
OMCL stock opened at $33.64 on Thursday. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 0.85 and a beta of 0.97. Omnicell, Inc. has a 1-year low of $29.06 and a 1-year high of $55.00. The firm has a fifty day moving average price of $38.90 and a two-hundred day moving average price of $39.17. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43.
Omnicell (NASDAQ:OMCL – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. During the same quarter last year, the company posted $0.45 earnings per share. Omnicell’s revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts predict that Omnicell, Inc. will post 1.41 EPS for the current year.
Omnicell Profile
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Featured Stories
- Five stocks we like better than Omnicell
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Free Report).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
